The abstract is read at the publisher; the summary is JClub's.
Duvakitug induced clinical remission at week 14 in adults with moderately to severely active ulcerative colitis, with 26% higher posterior response versus placebo at 900 mg.
- Why it matters: Ulcerative colitis remains difficult to treat for adults with inadequate response, loss of response, or intolerance to prior therapies, creating a need for effective and safe options.
- What they did: In a multicentre phase 2b trial, adults aged 18–75 were randomized 1:1:1 to duvakitug 2250 mg loading then 450 mg or 900 mg every 2 weeks, or placebo, with Bayesian analysis of modified Mayo remission at week 14.
- The result: Week 14 remission occurred in 36% (450 mg) and 48% (900 mg) versus 20% with placebo, with posterior probabilities exceeding the prespecified efficacy threshold and similar adverse event rates across groups.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.